Ra Pharmaceuticals Inc (RARX) Rating Reiterated by Jefferies Group
Ra Pharmaceuticals Inc (NASDAQ:RARX)‘s stock had its “buy” rating reissued by equities research analysts at Jefferies Group in a note issued to investors on Wednesday.
The analysts wrote, “Roughly in-line 3Q16 net loss of $8.1M; our estimated cash of $116M at end- FY16 should be at least sufficient into 2H18 based on our forecast. Key catalyst is Ph2 data for lead product RA101495 in PNH pts in 2H17; if positive (similar to Soliris), we view >100% potential upside as likely from current levels.””
Other analysts also recently issued research reports about the company. SunTrust Banks Inc. assumed coverage on Ra Pharmaceuticals in a research note on Monday, November 21st. They issued a “buy” rating and a $32.00 price target on the stock. Credit Suisse Group AG assumed coverage on Ra Pharmaceuticals in a research note on Monday, November 21st. They issued an “outperform” rating and a $19.00 price target on the stock. Finally, BMO Capital Markets assumed coverage on Ra Pharmaceuticals in a research note on Monday, November 21st. They set an “outperform” rating and a $26.00 target price on the stock.
Shares of Ra Pharmaceuticals (NASDAQ:RARX) traded up 0.3346% during mid-day trading on Wednesday, hitting $13.0435. The company’s stock had a trading volume of 11,800 shares. The company’s market cap is $7.23 million. The stock’s 50 day moving average price is $13.16 and its 200 day moving average price is $13.16. Ra Pharmaceuticals has a 52-week low of $12.33 and a 52-week high of $14.86.
In other Ra Pharmaceuticals news, Director Rajeev M. Shah bought 161,538 shares of the business’s stock in a transaction on Monday, October 31st. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $2,099,994.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Harry R. Weller bought 338,462 shares of the business’s stock in a transaction on Monday, October 31st. The shares were acquired at an average price of $13.00 per share, for a total transaction of $4,400,006.00. The disclosure for this purchase can be found here.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.